Bernard Fromenty - Toxicology

Author Information

Bernard Fromenty is an established researcher affiliated with several prestigious institutions in France, including INSERM, INRA, Université de Rennes, UBL, and Institut Cochin at Université Paris V René Descartes. His work is centered around the intersection of nutrition, metabolism, and cancer, specifically through the NuMeCan research unit in Rennes. Bernard Fromenty is also associated with Sanofi's Investigative Toxicology unit in Alfortville, indicating a strong collaboration between academia and industry in his research endeavors.

Research Contributions

Bernard Fromenty has made significant contributions to the field of toxicology, particularly in understanding drug-induced liver injuries and metabolic diseases. His recent publications include studies on the impact of acetaminophen and other xenobiotics on liver health, the role of mitochondrial dysfunction in disease progression, and the mechanisms of drug-induced hepatic steatosis. His research often utilizes advanced preclinical models to explore the molecular mechanisms underlying drug toxicity, with a focus on liver health and metabolic disorders. The breadth of his work highlights his dedication to unraveling complex toxicological processes and contributing to safer pharmaceutical practices.

Aliases

Bernard Fromenty is also known by various aliases including B Fromenty and B. Fromenty. These variations are commonly used in scientific publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	12,470
h-index	60
Total Number of Papers	178

Publications:

Acetaminophen (APAP, paracetamol) interferes with the first trimester human fetal ovary development in an ex vivo model.

DOI: 10.1210/clinem/dgac080

Year: 2022

Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease

DOI: 10.3390/ijms23031062

Year: 2022

Beneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction

DOI: 10.1073/pnas.2115139119

Year: 2022

Role of Mitochondrial Cytochrome P450 2E1 in Healthy and Diseased Liver

DOI: 10.3390/cells11020288

Year: 2022

Transcriptomic analysis in zebrafish larvae identifies iron-dependent mitochondrial dysfunction as a possible key event of NAFLD progression induced by benzo[a]pyrene/ethanol co-exposure.

DOI: 10.1007/s10565-022-09706-4

Year: 2022

Hepatotoxicity in NAFLD: acetaminophen and other xenobiotics

DOI: 10.1016/s0378-4274(21)00383-0

Year: 2021

Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients

DOI: 10.3390/ijms23010082

Year: 2021

ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET].

DOI: 10.1016/j.jhep.2021.06.021

Year: 2021

Non-oxidative ethanol metabolism in human hepatic cells in vitro: Involvement of uridine diphospho-glucuronosyltransferase 1A9 in ethylglucuronide production.

DOI: 10.1016/J.TIV.2020.104842

Year: 2020

Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity

DOI: 10.1007/s10565-020-09537-1

Year: 2020

What are the Key Components of ITS?

What are the Benefits of Using 4 Factor PCC?

What Are the Key Tools Used in Quantum Chemistry for Toxicology?

What Are the Implications for Public Health and Safety?

What Are Toxicological Endpoints?

Are Organic Foods Safer?

How Does Wastewater Treatment Impact the Environment?

What Are Some Common Bone Marrow Toxins?

What Are the Challenges of Bioaugmentation?

What Challenges are Faced in Remediation?

Partnered Content Networks

Relevant Topics